Referring for Faecal Microbiota Transplant (FMT) 

Overview 

Faecal Microbiota Transplant (FMT) is a therapeutic procedure that involves transferring faecal matter from a healthy, screened donor into the gastrointestinal tract of a recipient. The goal is to correct gut dysbiosis by restoring a healthy and diverse microbiome. This advanced therapy is increasingly recognised for treating conditions linked to disruptions in gut flora. 

Clinical Presentations 

Referral may be considered for patients with: 

  • Recurrent C. difficile infection not responding to standard antibiotics 
  • Inflammatory bowel disease (IBD), including Ulcerative Colitis (UC) or Crohn’s Disease (CD) 
  • Irritable Bowel Syndrome (IBS) with persistent symptoms 
  • Other emerging indications such as Parkinson’s disease, metabolic syndrome, diabetes, or cognitive/mental health disorders (investigational) 

How to Refer 

Submit a standard gastroenterology referral, noting “FMT assessment”, and include: 

  • Patient history, including prior infections and treatments 
  • Relevant investigations (blood tests, stool tests, imaging, previous endoscopy if applicable) 
  • Current medications and immune status 

Referral can be sent via Medical Objects or directly to admin@mygutcare.com.au. 

Prerequisites 

  • Assessment of infection status via blood and stool tests 
  • Endoscopic evaluation (colonoscopy) as required 
  • Review of medications and immune status 
  • Ensure patient suitability for FMT under specialist guidance 

How We Care for Your Patients 

  • Comprehensive assessment by a gastroenterologist 
  • Use of donor stool sourced from regulated stool banks following strict national and international guidelines  
  • Preparation and administration of FMT under controlled laboratory and clinical conditions 
  • Follow-up to monitor treatment response and address any side effects 

Safety Profile: 

  • FMT is generally safe under medical supervision 
  • Common mild side effects: bloating, cramping, abdominal discomfort, transient changes in bowel habits 
  • Serious adverse events are rare (<1%), primarily related to infectious transmission if donor screening is inadequate 
  • Not suitable for severely immunocompromised patients, pregnant/breastfeeding individuals, or those with certain chronic conditions 

Patient Resources 

 

References 

  1. Borody TJ, Paramsothy S, Agrawal G. Curr Gastroenterol Rep. 2013;15(8):337. 
  2. Choi HH, Cho YS. Clin Endosc. 2016;49(3):257–65. 
  3. Gulati M, Singh SK, et al. Pharmacol Res. 2020;159:104954. 
  4. Ramai D, Zakhia K, et al. Dig Dis Sci. 2021;66(2):369–80. 
  5. Cammarota G, Ianiro G, et al. Gut. 2017;66(4):569–80. 6–25.